Please login to the form below

Not currently logged in
Email:
Password:

tivozaniv

This page shows the latest tivozaniv news and features for those working in and with pharma, biotech and healthcare.

EUSA receives European green light for kidney cancer treatment Fotivda

EUSA receives European green light for kidney cancer treatment Fotivda

The European Commission (EC) has approved EUSA Pharma’s vascular endothelial growth factor receptor (VEGFR) inhibitor Fotivda (tivozaniv) as a first-line treatment for adults with advanced renal cell carcinoma (RCC).

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Apex.co.uk Conferences, Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics